Affordable Access

deepdyve-link
Publisher Website

Perspectives towards antiviral drug discovery against Ebola virus.

Authors
  • Mirza, Muhammad Usman1
  • Vanmeert, Michiel1
  • Ali, Amjad2, 3
  • Iman, Kanzal4
  • Froeyen, Matheus1
  • Idrees, Muhammad3, 5
  • 1 Department of Pharmaceutical Sciences, REGA Institute for Medical Research, Medicinal Chemistry, KU Leuven, Leuven, Belgium. , (Belgium)
  • 2 Department of Genetics, Hazara University, Mansehra, Pakistan. , (Pakistan)
  • 3 Molecular Virology Laboratory, Centre for Applied Molecular Biology (CAMB), University of the Punjab, Lahore, Pakistan. , (Pakistan)
  • 4 Biomedical Informatics Research Laboratory (BIRL), Department of Biology, Lahore University of Management Sciences (LUMS), Lahore, Pakistan. , (Pakistan)
  • 5 Hazara University Mansehra, Khyber Pakhtunkhwa Pakistan. , (Pakistan)
Type
Published Article
Journal
Journal of Medical Virology
Publisher
Wiley (John Wiley & Sons)
Publication Date
Dec 01, 2019
Volume
91
Issue
12
Pages
2029–2048
Identifiers
DOI: 10.1002/jmv.25357
PMID: 30431654
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Ebola virus disease (EVD), caused by Ebola viruses, resulted in more than 11 500 deaths according to a recent 2018 WHO report. With mortality rates up to 90%, it is nowadays one of the most deadly infectious diseases. However, no Food and Drug Administration-approved Ebola drugs or vaccines are available yet with the mainstay of therapy being supportive care. The high fatality rate and absence of effective treatment or vaccination make Ebola virus a category-A biothreat pathogen. Fortunately, a series of investigational countermeasures have been developed to control and prevent this global threat. This review summarizes the recent therapeutic advances and ongoing research progress from research and development to clinical trials in the development of small-molecule antiviral drugs, small-interference RNA molecules, phosphorodiamidate morpholino oligomers, full-length monoclonal antibodies, and vaccines. Moreover, difficulties are highlighted in the search for effective countermeasures against EVD with additional focus on the interplay between available in silico prediction methods and their evidenced potential in antiviral drug discovery. © 2018 Wiley Periodicals, Inc.

Report this publication

Statistics

Seen <100 times